International Journal of Infectious Diseases (Aug 2024)

Clinical, molecular, and drug resistance epidemiology of HIV in Jordan, 2019-2021: A national study

  • Faris G. Bakri,
  • Heyam H. Mukattash,
  • Hiam Esmeiran,
  • Glenna Schluck,
  • Casey K. Storme,
  • Erica Broach,
  • Tsedal Mebrahtu,
  • Mohammad Alhawarat,
  • Anais Valencia-Ruiz,
  • Oussama M'Hamdi,
  • Jennifer A. Malia,
  • Zebiba Hassen,
  • Mah'd M.S. Shafei,
  • Ala Y. Alkhatib,
  • Mahmoud Gazo,
  • Saied A. Jaradat,
  • Yessenia Gomez,
  • Samantha McGeehon,
  • Melanie D. McCauley,
  • Sarah C. Moreland,
  • Janice M. Darden,
  • Mihret Amare,
  • Trevor A. Crowell,
  • Sandhya Vasan,
  • Nelson L. Michael,
  • Julie A. Ake,
  • Kayvon Modjarrad,
  • Paul T. Scott,
  • Sheila A. Peel,
  • Shilpa Hakre

Journal volume & issue
Vol. 145
p. 107079

Abstract

Read online

Background: Limited epidemiologic studies have been conducted in Jordan describing the HIV epidemic. This study aimed to address this gap to inform HIV prevention and control. Methods: A nationally-representative cross-sectional study was conducted among adults living with HIV in Jordan. Laboratory testing included HIV viral load and next-generation-sequencing-based clinical genotype. Log-binomial regression estimated risk ratios (RRs) and 95% confidence intervals (CIs). Results: Among 231 (70%) participants, most were male (184/80%), and from Jordan (217/94%). Among 188 treatment-experienced-participants (>6 months), 165 (88%) were virally suppressed. High-level resistance was most frequent against nucleoside reverse transcriptase inhibitor (13/81%), and integrase-strand transfer inhibitor (INSTI) (10/62%) drugs among viremic (≥1000 HIV copies/mL) treatment-experienced participants with drug-resistant mutations (DRMs, n = 16). Common HIV subtypes (n = 43) were B (6/14%), A1 (5/12%), and CRF01_AE (5/12%); additionally, novel recombinant forms were detected. In multivariate analysis, independently higher risk for late diagnosis (n = 49) was observed with diagnosis through blood donation (vs check-up: RR 2.20, 95%CI 1.16-4.17) and earlier time-period of diagnosis (1986-2014 vs 2015-2021: RR 2.87, 95%CI 1.46-5.62). Conclusions: Late diagnosis and INSTI resistance endanger national HIV prevention and treatment in Jordan—high-level resistance to INSTI suggests therapeutic drug monitoring is needed for treatment efficacy and conservation of treatment options.

Keywords